
Network-1 Reports First Quarter 2025 Financial Results
Network-1 had revenue of $150,000 for the quarter ended March 31, 2025 as compared to no revenue for the quarter ended March 31, 2024. Revenue in 2025 was from a litigation settlement involving Network-1's Remote Power Patent. Network-1's operating expenses decreased by $123,000 in 2025 compared to 2024, primarily due to a decrease of $98,000 in professional fees as a result of a decrease in spending on litigation.
Network-1 reported a net loss of $363,000or $0.02per share basic and diluted for the quarter ended March 31, 2025, compared to a net loss of $920,000 or $0.04 per share on a basic and diluted basis for the quarter ended March 31, 2024. Included in the net loss is Network-1's share of the net loss of its equity investee (ILiAD Biotechnologies, LLC) of $462,000 and $628,000 for the quarters ended March 31, 2025 and 2024, respectively.
Interest and dividend income for the quarter ended March 31, 2025 was $484,000 as compared to $431,000for the quarter ended March 31, 2024. In addition, in the quarter ended March 31, 2025 Network-1 recorded realized and unrealized gains on marketable securities of $149,000 as compared to $48,000in the quarter ended March 31, 2024.
On March 31, 2025, Network-1 acquired a patent portfolio from IoT and M2M Technologies, LLC, relating to, among other things, enabling technology to support the interoperability of smart home IoT devices (the "Smart Home Patent Portfolio"). The Smart Home Patent Portfolio currently consists of eight (8) U.S. patents and one (1) international patent as well as eleven (11) U.S. pending patent applications and five (5) pending international patents.
At March 31, 2025, Network-1's principal sources of liquidity consisted of cash and cash equivalents and marketable securities of $39,193,000 and working capital of $38,443,000. Management believes that based on Network-1's current cash, cash equivalents and marketable securities positions, Network-1 will have sufficient liquidity to fund its operations for the foreseeable future.
On June 14, 2023, Network‑1's Board of Directors authorized an extension and increase of Network‑1's Share Repurchase Program to repurchase up to $5,000,000 of shares of its common stock over the subsequent 24-month period. During the quarter ended March 31, 2025, Network‑1 repurchased an aggregate of 106,662 shares of its common stock pursuant to its Share Repurchase Program at a cost of approximately $146,857 (exclusive of commissions) or an average price per share of $1.38. Since inception of its Share Repurchase Program (August 2011) to March 31, 2025, Network‑1 has repurchased an aggregate of 10,480,894 shares of its common stock at a cost of approximately $20,130,211 (exclusive of commissions) or an average per share price of $1.92. Combined with the approximate $23,000,000 in dividends paid beginning in 2010 to date, Network-1 has returned, through such dividends and share repurchases, in excess of $43,000,000 to its shareholders.
Network-1's dividend policy consists of semi-annual cash dividends of $0.05 per share ($0.10 per share annually) which have been paid in March and September of each year. On February 19, 2025, Network-1's Board of Directors declared a semi-annual cash dividend of $0.05 per share which was paid on March 28, 2025 to all shareholders of record as of March 14, 2025. Network‑1's dividend policy undergoes a periodic review by its Board of Directors and is subject to change at any time depending upon Network‑1's earnings, financial requirements and other factors existing at the time.
ABOUT NETWORK-1 TECHNOLOGIES, INC.
Network-1 Technologies, Inc. is engaged in the acquisition, development, licensing and protection of its intellectual property and proprietary technologies. Network-1 works with inventors and patent owners to assist in the development and monetization of their patented technologies. Network-1 currently owns one hundred fourteen (114) U.S. patents and sixteen (16) international patents covering various technologies, including enabling technology for authenticating and using eSIM technology in Internet of Things ("IoT"), certain advanced technologies related to high frequency trading, technologies relating to document stream operating systems and the identification of media content and enabling technology to support, among other things, the interoperability of smart home IT devices. Network-1's current strategy includes efforts to monetize four patent portfolios (the M2M/IoT, HFT, Cox and Smart Home portfolios). Network-1's strategy is to focus on acquiring and investing in high quality patents which management believes have the potential to generate significant licensing opportunities as Network-1 has achieved with respect to its Remote Power Patent and Mirror Worlds Patent Portfolio. Network-1's Remote Power Patent has generated licensing revenue in excess of $188,000,000 from May 2007 through March 31, 2025. Network-1 has achieved licensing and other revenue of $47,150,000 through March 31, 2025 with respect to its Mirror Worlds Patent Portfolio.
This release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements address future events and conditions concerning Network-1's business plans. Such statements are subject to a number of risk factors and uncertainties as disclosed in the Network-1's Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission on February 28, 2025 including, among others, Network-1's uncertain revenue from licensing its intellectual property, uncertainty as to the outcome of pending litigation involving Network-1's HFT Patent Portfolio, whether Network-1 will be successful in its appeal to the Federal Circuit of the District Court judgment of non-infringement dismissing Network-1's litigation against Google and YouTube involving certain patents within our Cox Patent Portfolio, the ability of Network-1 to successfully execute its strategy to acquire or make investments in high quality patents with significant licensing opportunities, Network-1's ability to achieve revenue and profits from its Cox Patent Portfolio, M2M/IoT Patent Portfolio, HFT Patent Portfolio and Smart Home Portfolio, as well as a successful outcome on its investment in ILiAD Biotechnologies, LLC or other intellectual property it may acquire or finance in the future, the ability of Network-1 to enter into additional license agreements, uncertainty as to whether cash dividends will continue be paid, Network-1's ability to enter into strategic relationships with third parties to license or otherwise monetize their intellectual property, , the risk in the future of Network-1 being classified as a Personal Holding Company which may result in Network-1 issuing a special cash dividend to its stockholders, future economic conditions and technology changes and legislative, regulatory and competitive developments. Except as otherwise required to be disclosed in periodic reports, Network-1 expressly disclaims any future obligation or undertaking to update or revise any forward-looking statement contained herein.
Network-1's unaudited condensed consolidated statements of operations and condensed consolidated balance sheet are attached.
For additional details regarding the above referenced highlights, please see Network-1's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 filed with the SEC on May 9, 2025.
Contacts:
Network-1 Technologies, Inc.Corey M. Horowitz, Chairman and CEO(917) 692-0000
NETWORK-1 TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(UNAUDITED)
NETWORK-1 TECHNOLOGIES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
SOURCE: Network-1 Technologies, Inc.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
2 hours ago
- Business Wire
STEELCASE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Steelcase Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Steelcase Inc. (NYSE: SCS) to HNI Corporation (NYSE: HNI). Under the terms of the proposed transaction, shareholders of Steelcase will receive $7.20 in cash and 0.2192 shares of HNI common stock for each share of Steelcase that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit Kahn Swick & Foti, LLC 1100 Poydras St., Suite 960 New Orleans, LA 70163


Business Wire
2 hours ago
- Business Wire
HILLEVAX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of HilleVax, Inc.
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of HilleVax, Inc. (NasdaqGS: HLVX) to XOMA Royalty Corporation (NasdaqGM: XOMA). Under the terms of the proposed transaction, shareholders of HilleVax will receive $1.95 in cash per share, plus one non-transferable contingent value right, representing the right to receive additional payments under certain conditions. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit Kahn Swick & Foti, LLC 1100 Poydras St., Suite 960 New Orleans, LA 70163


Business Upturn
2 hours ago
- Business Upturn
Nxera Launches Broad Proprietary Pipeline Targeting Obesity and Chronic Weight Management
Pipeline led by a new proprietary oral small molecule GLP-1 agonist and six additional innovative programs targeting the GIP, Amylin and Apelin receptors, aiming to transform treatment landscape Designed to address emerging areas of patient need, including long-term weight management, co-morbid metabolic disorders, and muscle preservation during weight loss Tokyo, Japan and Cambridge, UK, 6 August 2025 – Nxera Pharma Co., Ltd. ('Nxera'; TSE: 4565) a technology-powered biopharmaceutical company, today announces the launch of a broad new pipeline strategically focused on advancing next-generation therapies for obesity and associated metabolic disorders. Independent to the productive drug discovery collaborations with Pfizer and Eli Lilly, Nxera has established, expanded and accelerated drug discovery efforts of its own proprietary pipeline across a broad range of validated GPCR targets in these major disorders. Chris Cargill, President and CEO of Nxera, commented: 'Nxera scientists were among the pioneers in elucidating the structure of the GLP-1 receptor and other key receptors being targeted, giving us a clear advantage in developing potentially best-in-class next generation drug candidates. For the past 12 months, Nxera scientists have been advancing a broad metabolic disease pipeline to capitalize independently on our differentiated science. Today, we reveal the addition of these programs to our discovery portfolio, and are confident in achieving significant progress over the mid-term, delivering clear value for shareholders and patients in the rapidly expanding obesity market, projected to exceed US$100 billion annually in global sales.' Central to Nxera's pipeline is its new, wholly owned oral small molecule GLP-1 agonist program, focussed on differentiated chemistry, which is distinct, independent and developed separately from Pfizer's PF-06954522, allowing Nxera full control to drive rapid progress. Complementing this program, Nxera is simultaneously accelerating the advancement of an additional six established GPCR-targeted programs focused on obesity and chronic weight management: Three small molecule agonist programs (GIP, Apelin, Amylin) One small molecule antagonist program (GIP) Two long-acting programs (targets undisclosed) Nxera's pipeline leverages its proprietary NxWave™ GPCR-focused structure-based design platform to rapidly identify unique, highly differentiated lead molecules with novel chemistry. This process utilizes Nxera's NxHit proprietary small molecule libraries and NxStaR proteins for DNA encoded library (DEL) screening, distinguishing these candidates from others currently in discovery and clinical development globally. Nxera's focused approach is designed to deliver highly effective therapies addressing critical patient needs: Long-term weight maintenance: Convenient, scalable oral therapies for sustained weight loss. Convenient, scalable oral therapies for sustained weight loss. Targeting key obesity-related co-morbidities: Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Enhanced outcomes in cardiovascular, renal, and liver diseases, with new therapeutic indications emerging continuously. Reducing side effects and broadening out to difficult to treat populations: Targeted treatments for elderly, post-menopausal, and sarcopenic populations. Backed by an expert team with deep experience in GPCR drug discovery, Nxera is strategically positioned to be a leader in developing the next generation of best-in-class obesity and metabolic therapies. Nxera maintains its strong commitment to other key therapeutic areas including neurology, gastroenterology, and immunology, continuing to leverage the NxWave™ platform's proven capabilities in these domains. Separately, Nxera notes that Pfizer yesterday discontinued development of its Phase 1 candidate PF-06954522, a separate small molecule GLP-1 agonist, which was discovered under a strategic drug discovery collaboration with Nxera. This discontinuation by Pfizer was due to a portfolio decision and not because of any adverse safety findings. Nxera intends to enter discussions with Pfizer regarding potential opportunities to advance GLP-1 molecules discovered by Pfizer under the collaboration. Nxera will announce its earnings results and present operational highlights for Q2 2025 on Friday, 8 August 2025. –END– About Nxera Pharma Nxera Pharma is a technology powered biopharma company in pursuit of new specialty medicines to improve the lives of patients with unmet needs in Japan and globally. We have built an agile, new-generation commercial business in Japan to develop and commercialize innovative medicines, including several launched products, to address this high value, large and growing market and those in the broader APAC region. Behind that, and powered by our unique NxWave™ discovery platform, we are advancing an extensive pipeline of over 30 active programs from discovery through to late clinical stage internally and in partnership with leading pharma and biotech companies. This pipeline of potentially first- and best-in-class candidates is focused on addressing major unmet needs in some of the fastest-growing areas of medicine across obesity and metabolic disorders, neurology/neuropsychiatry and immunology and inflammation. Nxera employs approximately 400 talented people at key locations in Tokyo and Osaka (Japan), London and Cambridge (UK), Basel (Switzerland) and Seoul (South Korea) and is listed on the Tokyo Stock Exchange (ticker: 4565). For more information, please visit LinkedIn: @NxeraPharma | X: @NxeraPharma | YouTube: @NxeraPharma Enquiries: Nxera – Media and Investor RelationsShinya Tsuzuki, VP, Head of Investor RelationsShinichiro Nishishita, VP Investor Relations, Head of Regulatory DisclosuresMaya Bennison, Communications Manager +81 (0)3 5962 5718 | +44 (0)1223 949390 |[email protected]